LYELL IMMUNOPHARMA, INC. 401(K) PLAN
ERISA Form 5500 plan record drawn from DOL EBSA — verify with linked source filings below.
LYELL IMMUNOPHARMA, INC.
This 401(k) plan holds $24M in total assets and serves 265 participants as of 2023. It is sponsored by LYELL IMMUNOPHARMA, INC. in California. The plan reported positive net income of $9M for the year.
What the Filing Says About LYELL IMMUNOPHARMA, INC. 401(K) PLAN
LYELL IMMUNOPHARMA, INC. 401(K) PLAN is a 401(k) retirement plan sponsored by LYELL IMMUNOPHARMA, INC., headquartered in California. As of the 2023 Form 5500 filing, the plan reports $24M in total end-of-year assets and covers 265 participants across the Professional & Technical Services industry. The sponsor's EIN on file with the U.S. Department of Labor is 831300510, and the plan has been effective since 2019-01-01. Its filing status is currently FILING RECEIVED.
Year over year, total assets moved from $15M at the beginning of 2023 to $24M at year-end — a gain of 58.0%. Net assets (after liabilities) closed the year at $24M, with reported net income of $9M driven by investment returns, contributions received, and benefit payments during the period. These figures reflect what the plan administrator certified on Schedule H or Schedule I of the Form 5500 annual return and can be compared against 2 prior plan-year filings from the same sponsor shown below.
Asset totals and participant counts reflect a single plan year snapshot and can change materially with market conditions, plan mergers, or workforce changes. Fields such as "net income" include both realized investment performance and contribution/distribution flows — a single-year figure does not by itself indicate plan health or participant outcomes. This page summarizes public DOL disclosures for research and educational purposes only and is not retirement, tax, legal, or financial advice. Before making decisions about your own retirement benefits or evaluating an employer's plan, verify the underlying filing directly via the DOL EFAST2 system and consult a qualified professional.
Financial Summary (2023)
| Total Assets (Beginning of Year) | $15M |
| Total Assets (End of Year) | $24M |
| Net Assets (End of Year) | $24M |
| Net Income | $9M |
| Plan Type | 401(k) |
| Employer EIN | 831300510 |
| Plan Effective Date | 2019-01-01 |
| Filing Status | FILING RECEIVED |
Sponsor Plan History (LYELL IMMUNOPHARMA, INC.)
| Year | Plans | Participants | Total Assets |
|---|---|---|---|
| 2022 | 1 | 207 | $15M |
| 2023 | 1 | 265 | $24M |
| 2024 | 1 | 231 | $28M |
Nearby 401(k) Plans in California
Peer 401(k) plans — same state, same plan type — ranked by total assets.
- WELLS FARGO & COMPANY 401(K) PLAN $51.8B · 193,919
- GOOGLE LLC 401(K) SAVINGS PLAN $39.0B · 122,867
- ORACLE CORPORATION 401(K) SAVINGS AND INVESTMENT PLAN $26.3B · 63,105
- INTEL 401(K) SAVINGS PLAN $22.2B · 59,863
- APPLE 401(K) PLAN $19.8B · 106,111
Related Data
Guides
Related Data on Other Portals
Frequently Asked Questions
How much money is in the LYELL IMMUNOPHARMA, INC. 401(K) PLAN? ▼
What type of plan is LYELL IMMUNOPHARMA, INC. 401(K) PLAN? ▼
Who sponsors the LYELL IMMUNOPHARMA, INC. 401(K) PLAN? ▼
How did LYELL IMMUNOPHARMA, INC. 401(K) PLAN perform in 2023? ▼
Where can I find official filings for LYELL IMMUNOPHARMA, INC. 401(K) PLAN? ▼
How does LYELL IMMUNOPHARMA, INC. 401(K) PLAN compare to other plans? ▼
Explore PlainRetire
Source: U.S. Department of Labor, Employee Benefits Security Administration (EBSA), Form 5500 public disclosure dataset. Plan year 2023.
Source: DOL EFAST2 filing system (efast.dol.gov) — original filing retrieval by EIN 831300510.
Reference: IRS Publication 560 — Retirement Plans for Small Business, contribution-limit rules.
Reference: IRS Publication 590-B — Distributions from IRAs, RMD rules under SECURE Act 2.0.
Read our methodology — how this data is sourced, computed, and verified.